华兰生物(002007.SZ)参股公司收到药品注册受理通知书

Core Viewpoint - The company announced that its affiliate, Hualan Gene Engineering Co., Ltd., received a notice of acceptance for the production registration application of denosumab injection from the National Medical Products Administration, marking a significant step towards market entry for this biosimilar drug [1]. Group 1: Product Development - The denosumab injection developed by the company is a biosimilar drug, with the original product developed by Amgen and approved in multiple countries for treating various bone diseases, including osteoporosis and giant cell tumors [1]. - Denosumab is a humanized monoclonal antibody (IgG2 type) that specifically targets RANKL, a key factor necessary for the formation, function, and survival of osteoclasts [1]. Group 2: Market Context - Currently, four companies in China have received approval for denosumab injection, including Jiangsu Taikang Biopharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., Shandong Boan Biotechnology Co., Ltd., and Cangzhou Jereh Biotech Co., Ltd. [2]. - If Hualan Gene Engineering Co., Ltd. receives approval, it will enhance the product portfolio of the company and provide a new profit growth point [2].